Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.48 |
| ▸ | SLC10A1 | Q14973 | 4/20 | 0.47 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30103330 | 0.93 | CA1 (0.55) | CA1CA2NR1H4GPBAR1SLC10A1 | |
| SCHEMBL26426121 | 0.91 | CA1 (0.53) | CA1CA2 | |
| SCHEMBL26425773 | 0.91 | NR1H4 (0.64) | CA1CA2NR1H4GPBAR1SLC10A1 | |
| SCHEMBL30103315 | 0.91 | NR1H4 (0.64) | CA1CA2NR1H4GPBAR1SLC10A1 | |
| SCHEMBL26425786 | 0.91 | NR1H4 (0.64) | CA1CA2NR1H4GPBAR1SLC10A1 | |
| SCHEMBL26424157 | 0.90 | CA1 (0.51) | CA1CA2NR1H4GPBAR1SLC10A1 | |
| SCHEMBL23704729 | 0.89 | CA1 (0.55) | CA1CA2NR1H4GPBAR1SLC10A1 | |
| SCHEMBL23704726 | 0.89 | CA1 (0.55) | CA1CA2NR1H4GPBAR1SLC10A1 | |
| SCHEMBL23704743 | 0.87 | CA1 (0.53) | CA1CA2 | |
| SCHEMBL23705051 | 0.86 | NR1H4 (0.63) | CA1CA2NR1H4GPBAR1SLC10A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
| WO-2021155167-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | CA1 3966/4885CA2 2810/4885NR1H4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.